See Detailed Description
Data Collection
Acquired Immunodeficiency Syndrome+37
+ Acquired Immunodeficiency Syndrome
+ Acquired Immunodeficiency Syndrome
Treatment Study
Summary
Study start date: May 1, 2004
Actual date on which the first participant was enrolled.A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.866 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * HIV infected subjects that are naive to anti-HIV therapy. * History of a positive HIV test. * At least 1000 copies/mL of HIV in their blood as screening. Exclusion Criteria: * Active HIV-related diseases. * Taking other investigational drugs. * Pregnant or breastfeeding females. * Not be suitable to participate per investigator opinion.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 120 locations
GSK Investigational Site
Phoenix, United StatesGSK Investigational Site
Los Angeles, United StatesGSK Investigational Site
Sacramento, United States